As a melanocortin receptor agonist, bremelanotide (PT-141) is supplied as a sterile injectable solution. It helps address low sexual desire, most commonly hypoactive sexual desire disorder in premenopausal women, and is also used off-label to help support sexual arousal in men. Its effects are thought to work through central nervous system pathways rather than direct vascular action.
Compounding required for medical necessity.



Download a compounding order form for this medication with dose options and packaging choices.
Bremelanotide is a synthetic peptide that activates melanocortin receptors. Those receptors sit on nerve cells in the brain and on pigment cells in the skin. Two of them matter most at usual doses: MC4R, found in the central nervous system in areas linked to sexual desire, and MC1R, found on melanocytes.
How that receptor activity translates into a change in desire is not fully understood. What is established is the labeled use of the FDA-approved bremelanotide injection: treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women — low sexual desire that is distressing and is not explained by another medical or psychiatric condition, a relationship problem, or another medicine. That approved product is not indicated to enhance sexual performance, and it is not indicated for HSDD in men or in women after menopause.
Connect Wellness prepares compounded bremelanotide when a licensed prescriber determines a compounded form is medically necessary for an identified patient. We may compound it as a sterile subcutaneous injection, a non-sterile sublingual solution, or a non-sterile oral troche, as the prescription specifies. These preparations are not the FDA-approved product, are not substitutes for it, and have not been evaluated by the FDA for safety or effectiveness.